盐酸氨溴索联合重组人干扰素α2b雾化吸入治疗小儿病毒性上呼吸道感染的临床疗效

Clinical efficacy of ambroxol hydrochloride combined with recombinant human interferon α2b aerosol inhalation in the treatment of pediatric viral upper respiratory tract infection

目的探讨盐酸氨溴索联合重组人干扰素α2b雾化吸入治疗小儿病毒性上呼吸道感染的临床疗效。方法选取南通大学附属南通第三医院儿科门诊2016年5月—2017年5月收治的病毒性上呼吸道感染患儿80例,随机分为对照组与观察组,各40例。对照组患儿给予利巴韦林注射液治疗,观察组患儿采用注射用重组人干扰素联合盐酸氨溴索雾化吸入治疗,两组患儿均连续治疗5 d。比较两组患儿治疗前后血清炎性因子[肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、C反应蛋白]及主要临床指标(发热、咳嗽及全身症状)改善时间、临床疗效,并观察患儿不良反应发生情况。结果治疗前,两组患儿TNF-α、IL-6及C反应蛋白水平比较,差异无统计学意义(P>0.05);治疗后,观察组患儿TNF-α、IL-6及C反应蛋白水平低于对照组(P<0.05)。观察组患儿退热时间、咳嗽消退时间及全身症状消退时间短于对照组(P<0.05)。观察组患儿临床疗效优于对照组(P<0.05)。两组患儿均未见明显不良反应。结论盐酸氨溴索联合重组人干扰素α2b雾化吸入治疗小儿病毒性上呼吸道感染安全有效。

Objective To investigate the clinical efficacy of ambroxol hydrochloride combined with recombinant human interferon α2 b aerosol inhalation in the treatment of pediatric viral upper respiratory tract infection.Methods A total of 80 cases of children with viral upper respiratory tract infection were admitted from May 2016 to May 2017 in the Third Affiliated Hospital of Nantong University,which were randomly divided into control group and observation group,40 cases in each group.The control group was treated with ribavirin injection,observation group was treated with ambroxol hydrochloride combined with recombinant human interferon α2 b aerosol inhalation,both groups were treated for 5 days.The serum inflammatory factors（TNF-α,IL-6,C reactive protein） before and after treatment,improvement time of main symptoms（duration of fever,cough disappeared time and systemic symptoms subsided time） and clinical effect were compared between the two groups,and the incidence of adverse reactions were observed.Results Before treatment,no significant differences of TNF-α,IL-6 or C reactive protein was found between the two groups（P〈0.05）;after treatment,the TNF-α,IL-6 and C reactive protein in observation group were lower than control group（P〈0.05）.The observation group of duration of fever,cough disappeared time and systemic symptoms subsided time were shorter than control group（P〈0.05）.The clinical effect in observation group was better than control group（P〈0.05）.No serious adverse reactions was happened.Conclusion Ambroxol hydrochloride combined with recombinant human interferon α2 b aerosol inhalation have a effective and safe effect in the treatment of pediatric viral upper respiratory tract infection.